Physician profile
Matthew Helm
NPI 1346583150
$5,729.76
in general payments reported to CMS, 2019-2025
27 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $187 · 2021: $354 · 2022: $626 · 2023: $895 · 2024: $1,623 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,796 · Education: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,795.96 |
| Education | $494.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.07 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $701.95 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $600.24 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $474.87 | 2019-2025 | Taltz, Ebglyss |
| Amgen INC. | $467.63 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $463.41 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $184.43 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $182.06 | 2019-2023 | |
| Stryker Corporation | $178.25 | 2024 | Triathlon, Mesa Spinal System |
| Galderma Laboratories, L.P. | $147.27 | 2021-2025 | Nemluvio |
| Depuy Synthes Sales INC. | $134.31 | 2022 | |
| Allergan, INC. | $129.53 | 2020-2021 | |
| Leo Pharma INC. | $102.71 | 2023-2025 | Adbry, Anzupgo |
| Almirall LLC | $87.68 | 2021-2024 | Klisyri |
| Genzyme Corporation | $75.84 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.39 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $46.98 | 2023 | Vtama |
| Kerecis Limited | $31.97 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2023 | Cyltezo |
| Incyte Corporation | $25.41 | 2025 | Opzelura |
| Fresenius Kabi USA, LLC | $23.58 | 2024 | Idacio |
| Celgene Corporation | $21.22 | 2019 | |
| Springworks Therapeutics, INC. | $20.56 | 2025 | Gomekli |
| Convatec INC. | $19.74 | 2024 | |
| Arcutis Biotherapeutics, INC. | $17.42 | 2024 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $16.36 | 2025 | Valchlor |
| Genentech USA, INC. | $16.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.